| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 64 | 2024 | 782 | 11.160 |
Why?
|
| Down Syndrome | 25 | 2025 | 198 | 7.050 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 18 | 2024 | 128 | 2.890 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2023 | 85 | 2.300 |
Why?
|
| Leukemia, Myeloid, Acute | 10 | 2023 | 538 | 2.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2024 | 1252 | 1.740 |
Why?
|
| Leukemia | 6 | 2023 | 371 | 1.420 |
Why?
|
| Child | 88 | 2025 | 24173 | 1.220 |
Why?
|
| Methotrexate | 10 | 2024 | 337 | 1.200 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2025 | 1143 | 0.980 |
Why?
|
| Philadelphia Chromosome | 3 | 2024 | 41 | 0.940 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2024 | 184 | 0.930 |
Why?
|
| Ikaros Transcription Factor | 4 | 2021 | 28 | 0.930 |
Why?
|
| Disease-Free Survival | 16 | 2024 | 898 | 0.920 |
Why?
|
| Leukemoid Reaction | 1 | 2023 | 3 | 0.870 |
Why?
|
| Antineoplastic Agents | 8 | 2023 | 1695 | 0.870 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2023 | 40 | 0.850 |
Why?
|
| Lymphocyte Count | 3 | 2022 | 118 | 0.850 |
Why?
|
| Prognosis | 26 | 2024 | 4620 | 0.820 |
Why?
|
| Neoplasm, Residual | 6 | 2023 | 123 | 0.790 |
Why?
|
| Child, Preschool | 40 | 2025 | 13882 | 0.780 |
Why?
|
| Humans | 111 | 2025 | 124705 | 0.780 |
Why?
|
| Penetrance | 1 | 2020 | 102 | 0.680 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2023 | 1196 | 0.670 |
Why?
|
| Lymphoma | 1 | 2023 | 321 | 0.660 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 158 | 0.650 |
Why?
|
| Integrases | 1 | 2020 | 159 | 0.650 |
Why?
|
| Infant | 30 | 2024 | 12384 | 0.640 |
Why?
|
| Receptors, Cytokine | 4 | 2024 | 68 | 0.640 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2024 | 50 | 0.630 |
Why?
|
| Adolescent | 36 | 2024 | 19221 | 0.610 |
Why?
|
| Mycoses | 2 | 2021 | 118 | 0.590 |
Why?
|
| Gene Rearrangement | 4 | 2024 | 320 | 0.560 |
Why?
|
| Salvage Therapy | 1 | 2019 | 192 | 0.550 |
Why?
|
| Acute Disease | 8 | 2023 | 1107 | 0.530 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 725 | 0.520 |
Why?
|
| Male | 57 | 2025 | 61317 | 0.500 |
Why?
|
| Young Adult | 20 | 2024 | 9023 | 0.490 |
Why?
|
| B-Lymphocytes | 4 | 2021 | 533 | 0.480 |
Why?
|
| Janus Kinase 2 | 4 | 2017 | 131 | 0.470 |
Why?
|
| Genome-Wide Association Study | 7 | 2025 | 1686 | 0.470 |
Why?
|
| Recurrence | 9 | 2024 | 1415 | 0.470 |
Why?
|
| Female | 56 | 2025 | 66577 | 0.460 |
Why?
|
| Remission Induction | 2 | 2012 | 300 | 0.460 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2025 | 2634 | 0.440 |
Why?
|
| Self Report | 1 | 2017 | 517 | 0.440 |
Why?
|
| Transcription Factors | 3 | 2020 | 2594 | 0.430 |
Why?
|
| Mutation | 9 | 2023 | 5845 | 0.430 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 1708 | 0.400 |
Why?
|
| Steroids | 1 | 2013 | 201 | 0.390 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 265 | 0.370 |
Why?
|
| Bacterial Infections | 1 | 2014 | 308 | 0.370 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 3154 | 0.360 |
Why?
|
| Gene Deletion | 3 | 2021 | 789 | 0.360 |
Why?
|
| Treatment Failure | 1 | 2012 | 335 | 0.360 |
Why?
|
| DNA Methylation | 3 | 2021 | 1008 | 0.350 |
Why?
|
| Cell Proliferation | 6 | 2024 | 2303 | 0.350 |
Why?
|
| Chromosome Aberrations | 4 | 2023 | 612 | 0.350 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 238 | 0.340 |
Why?
|
| Genomics | 5 | 2024 | 1501 | 0.320 |
Why?
|
| Leukemia, Biphenotypic, Acute | 2 | 2019 | 5 | 0.320 |
Why?
|
| Dasatinib | 2 | 2020 | 41 | 0.310 |
Why?
|
| Metabolome | 2 | 2021 | 293 | 0.290 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 395 | 0.290 |
Why?
|
| Histones | 1 | 2011 | 525 | 0.280 |
Why?
|
| Residence Characteristics | 2 | 2020 | 278 | 0.280 |
Why?
|
| Point Mutation | 1 | 2008 | 347 | 0.280 |
Why?
|
| Neoplasms | 5 | 2024 | 2780 | 0.280 |
Why?
|
| Metabolomics | 2 | 2021 | 423 | 0.270 |
Why?
|
| Hematologic Neoplasms | 2 | 2021 | 283 | 0.240 |
Why?
|
| Mice | 11 | 2024 | 17645 | 0.240 |
Why?
|
| Leukapheresis | 1 | 2025 | 13 | 0.240 |
Why?
|
| Immunotherapy | 2 | 2024 | 675 | 0.240 |
Why?
|
| Treatment Outcome | 11 | 2024 | 12364 | 0.240 |
Why?
|
| Microfluidics | 1 | 2025 | 21 | 0.240 |
Why?
|
| Genotype | 6 | 2021 | 2558 | 0.240 |
Why?
|
| Osteosarcoma | 1 | 2008 | 253 | 0.240 |
Why?
|
| Laxatives | 1 | 2024 | 9 | 0.230 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 35 | 0.230 |
Why?
|
| Exome | 3 | 2022 | 1033 | 0.230 |
Why?
|
| Retrospective Studies | 15 | 2024 | 16263 | 0.230 |
Why?
|
| Case-Control Studies | 8 | 2025 | 3293 | 0.230 |
Why?
|
| Survival Rate | 7 | 2021 | 2055 | 0.220 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 38 | 0.220 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2024 | 48 | 0.220 |
Why?
|
| Mercaptopurine | 3 | 2019 | 71 | 0.220 |
Why?
|
| Animals | 15 | 2025 | 34235 | 0.220 |
Why?
|
| Constipation | 1 | 2024 | 114 | 0.220 |
Why?
|
| Risk Factors | 10 | 2025 | 10249 | 0.220 |
Why?
|
| PAX5 Transcription Factor | 2 | 2024 | 13 | 0.220 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 117 | 0.210 |
Why?
|
| Bone Neoplasms | 1 | 2008 | 420 | 0.210 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 5154 | 0.210 |
Why?
|
| Bone Marrow | 2 | 2022 | 323 | 0.210 |
Why?
|
| Imatinib Mesylate | 2 | 2020 | 45 | 0.210 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 2048 | 0.200 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 144 | 0.200 |
Why?
|
| Immunoglobulins | 1 | 2023 | 173 | 0.200 |
Why?
|
| Gene Frequency | 2 | 2021 | 724 | 0.190 |
Why?
|
| Adult | 14 | 2025 | 29554 | 0.190 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 139 | 0.190 |
Why?
|
| Monocytes | 2 | 2023 | 353 | 0.190 |
Why?
|
| Leukemia, Myeloid | 2 | 2013 | 85 | 0.190 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 183 | 0.180 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.180 |
Why?
|
| Alleles | 3 | 2021 | 1615 | 0.180 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2021 | 22 | 0.180 |
Why?
|
| Research Design | 1 | 2025 | 692 | 0.180 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2022 | 106 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2021 | 58 | 0.170 |
Why?
|
| Electronic Health Records | 2 | 2024 | 722 | 0.170 |
Why?
|
| Nervous System Neoplasms | 1 | 2020 | 11 | 0.170 |
Why?
|
| Incidence | 6 | 2024 | 3115 | 0.170 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 161 | 0.170 |
Why?
|
| Leukocyte Count | 3 | 2025 | 251 | 0.170 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2013 | 502 | 0.170 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 21 | 0.170 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2019 | 17 | 0.170 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 65 | 0.170 |
Why?
|
| Software | 1 | 2024 | 683 | 0.170 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 42 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 257 | 0.160 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 80 | 0.160 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 288 | 0.160 |
Why?
|
| Vehicle Emissions | 1 | 2019 | 19 | 0.160 |
Why?
|
| Social Class | 1 | 2020 | 190 | 0.160 |
Why?
|
| Karyotyping | 4 | 2015 | 323 | 0.160 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 3344 | 0.160 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2018 | 26 | 0.150 |
Why?
|
| Homozygote | 1 | 2021 | 547 | 0.150 |
Why?
|
| Models, Theoretical | 1 | 2021 | 359 | 0.150 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 556 | 0.150 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 1357 | 0.150 |
Why?
|
| Diploidy | 2 | 2008 | 37 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 187 | 0.150 |
Why?
|
| HEK293 Cells | 1 | 2021 | 737 | 0.150 |
Why?
|
| Infant, Newborn | 7 | 2022 | 8163 | 0.150 |
Why?
|
| Pyrazoles | 2 | 2024 | 305 | 0.150 |
Why?
|
| Neonatal Screening | 1 | 2020 | 184 | 0.150 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2018 | 65 | 0.150 |
Why?
|
| Maternal Exposure | 1 | 2019 | 148 | 0.140 |
Why?
|
| Air Pollutants | 1 | 2019 | 102 | 0.140 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 96 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2020 | 227 | 0.140 |
Why?
|
| Registries | 2 | 2022 | 1429 | 0.140 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2016 | 11 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 867 | 0.140 |
Why?
|
| Gene Fusion | 1 | 2017 | 55 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2022 | 1896 | 0.130 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 670 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2021 | 534 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 1090 | 0.130 |
Why?
|
| Genome, Human | 2 | 2021 | 1274 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 635 | 0.130 |
Why?
|
| Cognition Disorders | 1 | 2020 | 553 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 678 | 0.130 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 108 | 0.130 |
Why?
|
| Cell Line | 3 | 2013 | 2756 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2021 | 815 | 0.130 |
Why?
|
| Base Sequence | 2 | 2011 | 3101 | 0.130 |
Why?
|
| Risk | 2 | 2023 | 752 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2024 | 3444 | 0.130 |
Why?
|
| Immune Evasion | 1 | 2015 | 35 | 0.120 |
Why?
|
| Smad Proteins | 1 | 2015 | 43 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2017 | 332 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 728 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2015 | 763 | 0.120 |
Why?
|
| Biomarkers | 2 | 2021 | 3083 | 0.120 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2015 | 260 | 0.120 |
Why?
|
| Apoptosis | 2 | 2018 | 1802 | 0.120 |
Why?
|
| DNA | 1 | 2020 | 1606 | 0.110 |
Why?
|
| Dexamethasone | 3 | 2021 | 276 | 0.110 |
Why?
|
| Cohort Studies | 5 | 2024 | 4799 | 0.110 |
Why?
|
| Texas | 5 | 2022 | 3561 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2024 | 1052 | 0.110 |
Why?
|
| Antigens, Neoplasm | 2 | 2013 | 385 | 0.110 |
Why?
|
| Dendritic Cells | 2 | 2013 | 414 | 0.110 |
Why?
|
| Age Factors | 3 | 2021 | 2807 | 0.110 |
Why?
|
| Heart Defects, Congenital | 1 | 2025 | 1816 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 330 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2020 | 838 | 0.110 |
Why?
|
| Cytosol | 1 | 2013 | 161 | 0.110 |
Why?
|
| Electronics | 2 | 2023 | 43 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 459 | 0.100 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2013 | 30 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 572 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 605 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 414 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 327 | 0.100 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 164 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2012 | 135 | 0.090 |
Why?
|
| Central Nervous System | 2 | 2023 | 255 | 0.090 |
Why?
|
| Cellulitis | 1 | 2011 | 62 | 0.090 |
Why?
|
| Janus Kinase 1 | 1 | 2011 | 12 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2013 | 418 | 0.090 |
Why?
|
| Janus Kinase 3 | 1 | 2011 | 15 | 0.090 |
Why?
|
| Creatinine | 2 | 2023 | 391 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 722 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2023 | 284 | 0.090 |
Why?
|
| Immunophenotyping | 3 | 2019 | 329 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 410 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 304 | 0.090 |
Why?
|
| DNA Primers | 1 | 2011 | 656 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1238 | 0.080 |
Why?
|
| Nitriles | 2 | 2024 | 146 | 0.080 |
Why?
|
| Neutropenia | 1 | 2011 | 197 | 0.080 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2009 | 15 | 0.080 |
Why?
|
| Prednisone | 2 | 2020 | 271 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1504 | 0.080 |
Why?
|
| Asparaginase | 2 | 2020 | 41 | 0.080 |
Why?
|
| Leucovorin | 2 | 2020 | 49 | 0.080 |
Why?
|
| Cytarabine | 2 | 2020 | 98 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 294 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 573 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 3 | 2016 | 1062 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 656 | 0.080 |
Why?
|
| Vincristine | 2 | 2021 | 191 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 503 | 0.080 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 227 | 0.070 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 278 | 0.070 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2018 | 64 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2024 | 371 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2023 | 802 | 0.070 |
Why?
|
| Gene Editing | 2 | 2021 | 187 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2008 | 628 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 769 | 0.070 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 646 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2019 | 1253 | 0.060 |
Why?
|
| Cell Survival | 1 | 2008 | 812 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2008 | 603 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 4406 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2717 | 0.060 |
Why?
|
| Leukocytosis | 1 | 2025 | 46 | 0.060 |
Why?
|
| Sex Factors | 1 | 2008 | 1287 | 0.060 |
Why?
|
| Data Curation | 1 | 2024 | 12 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1578 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2023 | 1717 | 0.060 |
Why?
|
| Cell Separation | 1 | 2025 | 229 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2093 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 1807 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2008 | 885 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 184 | 0.050 |
Why?
|
| Leukocytes | 1 | 2025 | 210 | 0.050 |
Why?
|
| France | 1 | 2023 | 80 | 0.050 |
Why?
|
| WT1 Proteins | 2 | 2013 | 27 | 0.050 |
Why?
|
| Naphthyridines | 1 | 2023 | 7 | 0.050 |
Why?
|
| Oncogenes | 1 | 2004 | 167 | 0.050 |
Why?
|
| Genes, Immunoglobulin | 1 | 2023 | 33 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 214 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 1757 | 0.050 |
Why?
|
| Censuses | 1 | 2022 | 11 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 41 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 2161 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2025 | 649 | 0.050 |
Why?
|
| Obesity | 1 | 2013 | 2248 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 465 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 883 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2025 | 1243 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 1016 | 0.050 |
Why?
|
| Transcriptome | 2 | 2019 | 953 | 0.050 |
Why?
|
| Entropy | 1 | 2021 | 26 | 0.050 |
Why?
|
| Stochastic Processes | 1 | 2021 | 34 | 0.050 |
Why?
|
| Consolidation Chemotherapy | 1 | 2021 | 6 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 48 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 39 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1492 | 0.040 |
Why?
|
| United States | 3 | 2021 | 10866 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 925 | 0.040 |
Why?
|
| Arabinonucleosides | 1 | 2020 | 32 | 0.040 |
Why?
|
| Forecasting | 1 | 2022 | 352 | 0.040 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 34 | 0.040 |
Why?
|
| Sepsis | 1 | 2024 | 479 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 2021 | 245 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2020 | 124 | 0.040 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2019 | 9 | 0.040 |
Why?
|
| Genes, p16 | 1 | 2019 | 13 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 35 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2024 | 592 | 0.040 |
Why?
|
| Luciferases | 1 | 2019 | 132 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2020 | 218 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 56 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 103 | 0.040 |
Why?
|
| Seizures | 1 | 2024 | 870 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2018 | 3742 | 0.040 |
Why?
|
| World Health Organization | 1 | 2019 | 100 | 0.040 |
Why?
|
| Mucositis | 1 | 2019 | 19 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 285 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 210 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 142 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2013 | 780 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 101 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2025 | 519 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 432 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2021 | 288 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 749 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 332 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 539 | 0.040 |
Why?
|
| Etoposide | 1 | 2018 | 114 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 4258 | 0.040 |
Why?
|
| Air Pollution | 1 | 2019 | 66 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1022 | 0.040 |
Why?
|
| Proteome | 1 | 2020 | 243 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 359 | 0.040 |
Why?
|
| Rats | 1 | 2025 | 3728 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 19 | 0.040 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 167 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 199 | 0.040 |
Why?
|
| Pyrophosphatases | 1 | 2018 | 20 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 154 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 568 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2018 | 6132 | 0.040 |
Why?
|
| Guatemala | 1 | 2017 | 62 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 618 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 573 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1399 | 0.030 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2017 | 20 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 40 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 175 | 0.030 |
Why?
|
| Amino Acids | 1 | 2019 | 666 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2022 | 4534 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2020 | 383 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 810 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 1367 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 417 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 298 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 816 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 281 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1191 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 867 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 683 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 253 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 564 | 0.030 |
Why?
|
| Quality of Life | 1 | 2025 | 1936 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 162 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2014 | 137 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2014 | 124 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1625 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 522 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2013 | 32 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 778 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 684 | 0.030 |
Why?
|
| K562 Cells | 1 | 2013 | 95 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2013 | 26 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1892 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 69 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 48 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 2013 | 19 | 0.030 |
Why?
|
| Myeloblastin | 1 | 2013 | 18 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1701 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 524 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2019 | 1498 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 117 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2013 | 80 | 0.030 |
Why?
|
| Epilepsy | 1 | 2020 | 873 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 204 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 148 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2013 | 709 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 1631 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 4396 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 664 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 822 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1695 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 666 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2397 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 498 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 759 | 0.020 |
Why?
|
| Pediatrics | 1 | 2019 | 1144 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1437 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2043 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2013 | 494 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1752 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 949 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1958 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2885 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 3055 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 26884 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 19830 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2004 | 687 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 2524 | 0.010 |
Why?
|